Journal Characteristics
|
Journal Impact factor
|
Range 0.34–44.02 |
40/56 (71) |
1.010 (0.912, 1.130) |
0.8902 |
23/56 (41) |
0.924 (0.742, 1.138) |
0.4789 |
Mean Value = 4.63 |
|
|
|
|
|
|
Std deviation = 6.06 |
|
|
|
|
|
|
Median Value = 2.84 |
|
|
|
|
|
|
Study characteristics
|
Comparison Groups
|
Placebo Controlled trial |
27/28 (96) |
1.00 |
|
11/25 ( 44) |
1.00 |
|
Drug–drug Comparative trial |
15/33 (46) |
0.031 (0 , 0.245) |
0 |
14/24 (58) |
1.782 (0.499, 6.425) |
0.4736 |
Sample size
|
Range 20–4360 |
42/61 |
1.002 (1.000, 1.005) |
0.0394 |
25/49 |
0.999 (0.997, 1.001) |
0.3720 |
Mean Value = 390 |
|
|
|
|
|
|
Std deviation = 590.4 |
|
|
|
|
|
|
Median Value = 252 |
|
|
|
|
|
|
Study design characteristics aimed at reducing bias
|
Randomization/Concealment of allocation
|
Adequate |
11/15 (73) |
1.331 (0.320, 6.669) |
0.9292 |
5/10 (50) |
0.950 (0.186, 4.868) |
1.000 |
Blinding
|
Adequate |
30/36 (83) |
5.417 (1.459, 21.188) |
0.0081 |
11/28 (39) |
0.324 (0.083, 1.216) |
0.1066 |
ITT Analysis
|
Adequate |
36/48 (75) |
4.200 (0.922, 19.750) |
0.0664 |
18/38 (47) |
0.514 (0.095, 2.464) |
0.5453 |
Follow-up
|
Adequate |
31/49 (63) |
0.157 (0.003, 1.274) |
0.1061 |
20/40 (50) |
0.800 (0.138, 4.358) |
1.0000 |
Appropriate Medication Dosing
|
Test drug – Adequate |
42/60 (70) |
Infinite (0.057, Infinite) |
0.6230 |
25/48 (52) |
Infinite (0.027, Infinite) |
0.9796 |
Comparator drug - Adequate |
14/30 (47) |
1.750 (0.081, 110.507) |
1.0000 |
12/21 (57) |
0.667 (0.010, 14.997) |
1.0000 |
Author characteristics
|
Corresponding Author Institutional Affiliation
|
Test drug company |
16/16 (100) |
Infinite (0.410, Infinite) |
0.1176 |
8/13 (62) |
Infinite (0.034, Infinite) |
0.8571 |
Any other industry |
0/1 (0) |
– |
– |
0/1 (0) |
|
|
Academic/Hospital |
26/43 (61) |
Infinite (0.037, Infinite) |
0.8182 |
17/35 (49) |
Infinite (0.023, Infinite) |
1.0000 |
All Other |
0/1 (0) |
1.000 |
|
0/0 (0) |
|
|
Funding information
|
Funding source
|
Test drug company/any other industry/other drug companies |
0/2 (0) |
0 (0, 1.656) |
0.1111 |
2/2 (100) |
Infinite (0.092, Infinite) |
0.8667 |
Test drug company employee author/no formal disclosure |
1/2 (50) |
0.238 (0.003, 22.399) |
0.7778 |
2/2 (100) |
Infinite (0.092, Infinite) |
0.8667 |
Any other drug company |
2/6 (33) |
0.119 (0.009, 1.190) |
0.0769 |
0/5 (0) |
0 (0, 0.886) |
0.0373 |
No drug company |
1/1 (100) |
Infinite (0.006, Infinite) |
1.0000 |
0/1 (0) |
0 (0, 26.000) |
0.8000 |
No funding disclosure |
17/24 (71) |
0.578 (0.122, 2.590) |
0.6238 |
9/20 (45) |
0.477 (0.109, 2.043) |
0.4153 |
Test drug funding
|
Test drug funding |
22/30 (73) |
1.512 (0.445, 5.269) |
0.6416 |
16/23 (70) |
4.317 (1.126, 17.134) |
0.0300 |
Corresponding Author Financial Ties
|
Test drug company ties/any other industry ties |
2/5 (40) |
0.133 (0.002, 3.502) |
0.3939 |
2/3 (67) |
2.000 (0.061, 156.747) |
1.0000 |
Test drug company employee/no formal disclosure of ties |
15/15 (100) |
Infinite (0.064, Infinite) |
0.5714 |
8/12 (67) |
2.000 (0.173, 22.393) |
0.8552 |
Any other industry ties |
2/2 (100) |
Infinite (0.009, Infinite) |
1.0000 |
1/2 (50) |
1.000 (0.010, 104.374) |
1.0000 |
No disclosure of ties |
18/32 (56) |
0.257 (0.005, 2.776) |
0.4388 |
10/25 (40) |
0.667 (0.074, 6.103) |
0.9987 |
Corresponding Author Test Drug Financial Ties
|
Test drug financial ties |
22/26 (85) |
4.125 (1.048, 19.525) |
0.0409 |
13/21 (62) |
2.167 (0.592, 8.099) |
0.3025 |
First Author Financial Ties
|
Test drug company ties/any other industry ties |
2/5 (40) |
0 (0, 2.027) |
0.1667 |
2/3 (67) |
1.333 (0.036, 117.498) |
1.0000 |
Test drug company employee/no formal disclosure of ties |
5/5 (100) |
1.00 |
|
3/5 (60) |
1.000 (0.042, 23.663) |
1.0000 |
Any other industry ties |
2/2 (100) |
1.00 |
|
1/2 (50) |
0.667 (0.006, 78.249) |
1.0000 |
No disclosure of ties |
28/44 (64) |
0 (0, 2.188) |
0.2489 |
16/34 (47) |
0.593 (0.045, 5.955) |
0.9492 |
First Author Test Drug Financial Ties
|
Test drug financial ties |
12/15 (80) |
2.133 ((0.469, 13.331) |
0.4588 |
8/13 (62) |
1.788 (0.414, 8.297) |
0.5762 |